US2010222327A1PendingUtilityA1

Methods of Preparing Pharmaceutical Compositions Comprising Eslicarbazepine Acetate and Methods of Use

63
Assignee: PORTELA & CA SAPriority: May 6, 2005Filed: Aug 4, 2009Published: Sep 2, 2010
Est. expiryMay 6, 2025(expired)· nominal 20-yr term from priority
A61P 25/08A61P 25/18A61P 25/00A61P 25/06A61K 31/19A61K 31/55A61K 45/06
63
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present disclosure relates to the treatment of various diseases and conditions with eslicarbazepine acetate. The present disclosure also relates to the use of eslicarbazepine acetate in a method for reducing or decreasing epileptic seizures in a patient. The present disclosure also relates to a method for increasing the exposure to eslicarbazepine in a patient. The present disclosure also relates to a method of preparing a pharmaceutical composition comprising eslicarbazepine acetate.

Claims

exact text as granted — not AI-modified
1 - 29 . (canceled) 
   
   
       30 . A method for the treatment of at least one affective disorder or at least one bipolar disorder in a patient in need thereof, comprising administering to the patient a pharmacologically effective amount of eslicarbazepine acetate. 
   
   
       31 . The method according to  claim 30 , comprising administering to said patient an amount of eslicarbazepine acetate ranging between about 400 mg and about 2400 mg approximately every 24 hours. 
   
   
       32 . A method for the treatment of at least one manic symptom in a patient in need thereof, comprising administering to the patient a pharmacologically effective amount of eslicarbazepine acetate. 
   
   
       33 . A method for the maintenance treatment of at least one affective disorder or at least one bipolar disorder in a patient in need thereof, comprising administering to the patient a pharmacologically effective amount of eslicarbazepine acetate. 
   
   
       34 . The method according to  claim 33 , comprising administering to said patient an amount of eslicarbazepine acetate ranging between about 400 mg and about 2400 mg approximately every 24 hours.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.